In vivo study of the tissue distribution and immunosuppressive response of cyclosporin a-loaded polyester micro- and nanospheres

References

• Aziz S., Bieber C. P., Reitz B. A., Bieber M. M., Oyer P. E., Hogt G., Stinson E. B. Preparation and efficacy of cyclosporin-A liposomes for prolongation of cardiac allograft survival. Transplant Proc. 1981; 13(1)410–411
   PubMed Web of Science ®Google Scholar
• Bernareggi A., Rowland M. Physiologic modeling of cyclosporine kinetics in rat and man. J. Pharmacokinet. Biopharm. 1991; 19(1)21–51
   PubMedGoogle Scholar
• Cavanak T., Sucker H. Formulation of dosage forms. Prog. Allergy 1986; 38: 65–72
   PubMedGoogle Scholar
• Cunningham A. J., Szenberg A. Further improvements in the plaque technique for detecting single antibody forming cells. Immunology 1968; 14: 599–606
   PubMed Web of Science ®Google Scholar
• Cyert M. S. Immunosuppressants hit the target. Curr. Biol. 1992; 2: 18–20
   PubMedGoogle Scholar
• D'Souza M. J. Controlled release of cyclosporine from microspheres. Drug Dee. Md. Pharm. 1988; 14: 1351–1357
   Web of Science ®Google Scholar
• Eldridge J. H., Staas J. K., Meulbroeck J. A., Tice T. R., Gilley R. M. Biodegradable and biocompatible poly(d,l-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infec. Immun. 1991; 59: 2978–2986
   PubMed Web of Science ®Google Scholar
• Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez-Decampeneere D., Speiser P. Pharmacokinetics and distribution of a biodegradable drug carrier. Int. J. Pharm. 1983; 15: 335
   Web of Science ®Google Scholar
• Hanas E., Tufveson G., Lindgren P. G., Sjöberg O., Tötterman T. H. Concentrations of cyclosporin-A and its metabolites in transplanted human kidney tissue during rejection and stable graft function. Clin Transplant 1991; 5: 107–111
   Web of Science ®Google Scholar
• Hsieh H. H., Schreiber M., Stowe N., Novik A., Deodhar S., Barns B., Pippenger C., Shamberger R. Preliminary report: The use of liposome-encapsulated cyclosporine in a rat model. Transplant Proc 1985; 17(1)1397–1400
   Web of Science ®Google Scholar
• Kadir F., Eling W. M. C., Crommelin D. J. A., Zuidema J. Influence of injection volume on the release kinetics of liposomal chloroquine administered subcutaneously or intramuscularly to mice. J. Control. Rel. 1991; 17: 277–284
   Web of Science ®Google Scholar
• Krause H. J., Schwarz A., Rohdewald P. Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs. Int. J. Pharm. 1985; 27: 145–155
   Web of Science ®Google Scholar
• Kreuter J., Nefzger M., Liehl E., Czok R., Voges R. Distribution and elimination of poly(methyl methacrylate) nano-particles after subcutaneous administration to rats. J. Pharm. Sci. 1983; 72(10)1146–1149
   PubMed Web of Science ®Google Scholar
• Luke D. R., Kasiske B. L., Matzke G. R., Awni W. M., Keane W. F. Effects of cyclosporine on the isolated perfused rat kidney. Transplantation 1987; 43: 795–799
   PubMed Web of Science ®Google Scholar
• Maurer G., Lemaire M. Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant. Proc. 1986; 18: 25–34, (6, Suppl. 5)
   PubMed Web of Science ®Google Scholar
• Sánchez A., Alonso M. J. Poly(d,l-lactide-co-glycolide) micro and nanospheres as a way to prolong blood/plasma levels of subcutaneously injected cyclosporin A. 1993b, Submitted for publication
   Google Scholar
• Sánchez A., Vila-Jato J. L., Alonso M. J. Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin. A. Int. J. Pharm 1993a; 99: 263–273
   Web of Science ®Google Scholar
• Sandimmun^R practical guide. Sandoz, Ltd., BasleSwitzerland 1989
   Google Scholar
• Sawchuk R. J., Cartier L. L. Liquid-chromatographic determination of cyclosporin A in blood and plasma. Clin. Chem. 1981; 27: 1368–1371
   PubMed Web of Science ®Google Scholar
• Smeesters C., Giroux L., Vinet B., Arnoux R., Chaland P., Corman J., St-Louis G., Daloze P. Reduced nephrotoxicity of cyclosporine A after incorporation into liposomes. Transplant. Proc. 1988a; 20: 831–832, (3, Suppl. 3)
   PubMed Web of Science ®Google Scholar
• Smeesters C., Giroux L., Vinet B., Arnoux R., Chaland P., Corman J., St-Louis G., Daloze P. Efficacy of incorporating cyclosporine into liposomes to reduce its nephrotoxicity. Can. J. Surg. 1988b; 31: 34–36
   PubMed Web of Science ®Google Scholar
• Tice T. R., Mason D. W., Gilley R. M. Clinical use and future of parenteral microsphere delivery systems. “Novel Drug Delivery”, L. F. Prescott, W. S. Nimmo. Wiley, United Kingdom 1988; 223–235
   Google Scholar
• Tötterman T. H., Hanas E., Bergström R., Larsson E., Tufveson G. Immunological diagnosis of kidney rejection using FACS analysis of graft-infiltrating functional and activated T and NK cell subsets. Transplantation 1989; 47: 817
   PubMed Web of Science ®Google Scholar
• Ubeira F. M., Seoane R., Puentes E., Faro J., Regueiro B. J. Effect of clofibrate on the growth kinetics in murine P1798(sc) lymphoma. Br. J. Cancer 1983; 48: 417–421
   PubMed Web of Science ®Google Scholar
• Vadiei K., Lopez-Berenstein G., Perez-Soler R., Luke D. R. In vitro evaluation of liposomal cyclosporine. Int. J. Pharm. 1989b; 57: 133–138
   Web of Science ®Google Scholar
• Vadiei K., Lopez-Berestein G., Perez-Soler R., Luke D. R. Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine. Drug Met. Disp. 1991; 19(6)1147–1151
   PubMed Web of Science ®Google Scholar
• Vadiei K., Perez-Soler R., Lopez-Berestein G., Luke D. R. Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine. Int. J. Pharm. 1989a; 57: 125–131
   Web of Science ®Google Scholar
• Venkataram S., Awni W. M., Jordan K., Rahman Y. E. Pharmacokinetics of two alternative dosage forms for cyclosporine: Liposomes and intralipid. J. Pharm. Sci. 1990; 79(3)216–219
   PubMed Web of Science ®Google Scholar
• Veremis S. A., Maddux M. S., Tang I. Y. S., Millner S. N., Prasad R., Pollak R., Mozes M. F. Comparison of cyclosporine (CSA) blood levels and RIA/HPLC ratios among renal transplant patients with normal allograft functions, CSA nephrotoxicity or rejection. Transplant Proc. 1989; 21(1)1476–1477
   PubMed Web of Science ®Google Scholar
• Wassef R., Cohen Z., Langer B. Pharmacokinetic profiles of cyclosporine in rats. Transplantation 1985; 40(5)489–493
   PubMed Web of Science ®Google Scholar
• Yanagawa A., Iwagama T., Saotone T., Shoji Y., Takano K., Oka H., Nakagawa T., Mizushima Y. Selective transfer of cyclosporin to thoracic lymphatic systems by the application of lipid microspheres. J. Microencapsulation 1989; 6: 161–164
   PubMed Web of Science ®Google Scholar